[go: up one dir, main page]

AR110564A1 - Anticuerpos anti-il-5 - Google Patents

Anticuerpos anti-il-5

Info

Publication number
AR110564A1
AR110564A1 ARP170103611A ARP170103611A AR110564A1 AR 110564 A1 AR110564 A1 AR 110564A1 AR P170103611 A ARP170103611 A AR P170103611A AR P170103611 A ARP170103611 A AR P170103611A AR 110564 A1 AR110564 A1 AR 110564A1
Authority
AR
Argentina
Prior art keywords
human
antibody molecules
bind
antibodies
disclosed
Prior art date
Application number
ARP170103611A
Other languages
English (en)
Inventor
Bridget Ann Cooksey
David Jose Simon Laine
Adam Clarke
Anthony Doyle
Mark Terence Liddament
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR110564A1 publication Critical patent/AR110564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se divulgan moléculas de anticuerpo completamente humanas que se unen de manera inmunoespecífica a IL-5 humana. Las moléculas de anticuerpo se pueden unir a IL-5 humana con una constante de afinidad en equilibrio (KD) de por lo menos aproximadamente 40 pM según lo determinado mediante resonancia de plasmones superficiales.
ARP170103611A 2016-12-23 2017-12-20 Anticuerpos anti-il-5 AR110564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662438502P 2016-12-23 2016-12-23

Publications (1)

Publication Number Publication Date
AR110564A1 true AR110564A1 (es) 2019-04-10

Family

ID=60972458

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103611A AR110564A1 (es) 2016-12-23 2017-12-20 Anticuerpos anti-il-5

Country Status (20)

Country Link
US (2) US11111292B2 (es)
EP (1) EP3559030B1 (es)
JP (1) JP7060906B2 (es)
KR (1) KR102651290B1 (es)
CN (1) CN110267986B (es)
AR (1) AR110564A1 (es)
AU (1) AU2017379853B2 (es)
BR (1) BR112019012929A2 (es)
CA (1) CA3048186A1 (es)
CL (1) CL2019001730A1 (es)
EA (1) EA201991552A1 (es)
ES (1) ES2984636T3 (es)
IL (1) IL267271B2 (es)
MX (1) MX2019007642A (es)
NZ (1) NZ754606A (es)
PE (1) PE20191662A1 (es)
PH (1) PH12019501452A1 (es)
RU (1) RU2758008C2 (es)
WO (1) WO2018119016A1 (es)
ZA (1) ZA201904097B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела
AU2018273174B2 (en) 2017-05-26 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Biopharmaceutical compositions and related methods
CN111303284A (zh) * 2018-12-12 2020-06-19 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
BR112021019272A2 (pt) 2019-03-29 2022-01-04 Jiangsu Hengrui Medicine Co Composição farmacêutica contendo anticorpo contra il-5 e uso da mesma
CN112745389B (zh) * 2019-10-29 2022-11-25 瑞阳(苏州)生物科技有限公司 结合人il-5的单克隆抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
EP0800536B1 (en) * 1994-12-23 2006-11-29 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ES2327830T3 (es) * 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
KR20240099511A (ko) 2015-08-24 2024-06-28 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
TW201722989A (zh) * 2015-10-23 2017-07-01 輝瑞大藥廠 抗il-2抗體及其組合物及用途
EA201991552A1 (ru) * 2016-12-23 2020-01-09 Сефалон, Инк. Анти-il-5 антитела

Also Published As

Publication number Publication date
PE20191662A1 (es) 2019-11-11
WO2018119016A1 (en) 2018-06-28
JP7060906B2 (ja) 2022-04-27
IL267271B2 (en) 2025-10-01
CA3048186A1 (en) 2018-06-28
CL2019001730A1 (es) 2019-09-27
NZ754606A (en) 2023-06-30
EP3559030A1 (en) 2019-10-30
KR20190126769A (ko) 2019-11-12
US11111292B2 (en) 2021-09-07
RU2019123112A3 (es) 2021-04-05
US20210355205A1 (en) 2021-11-18
ZA201904097B (en) 2023-12-20
JP2020513761A (ja) 2020-05-21
IL267271A (en) 2019-08-29
MX2019007642A (es) 2019-09-09
CN110267986A (zh) 2019-09-20
RU2758008C2 (ru) 2021-10-25
PH12019501452A1 (en) 2020-06-15
AU2017379853B2 (en) 2025-02-06
ES2984636T3 (es) 2024-10-30
BR112019012929A2 (pt) 2019-12-10
IL267271B1 (en) 2025-06-01
EP3559030C0 (en) 2024-04-03
CN110267986B (zh) 2023-05-09
US20180186873A1 (en) 2018-07-05
KR102651290B1 (ko) 2024-03-25
EP3559030B1 (en) 2024-04-03
AU2017379853A1 (en) 2019-07-04
RU2019123112A (ru) 2021-01-26
EA201991552A1 (ru) 2020-01-09

Similar Documents

Publication Publication Date Title
AR110564A1 (es) Anticuerpos anti-il-5
ECSP17080639A (es) Moléculas de unión a lag-3 y métodos de uso de las mismas
CO2019013935A2 (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
SV2019005807A (es) Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso
EA201690813A1 (ru) Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
EA201691266A1 (ru) Анти-cd3 антитела и способы применения
UA120981C2 (uk) Антитіло, що зв'язується з il-8, та його застосування
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
PT3307322T (pt) Anticorpos anti-cp40 humanizados e as suas utilizações referência cruzada relativa às aplicações associadas
CR20180154A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
MX2015015970A (es) Anticuerpos receptores de antitransferina y metodos de uso.
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
MX351127B (es) Proteínas de unión al antígeno del receptor de oncostatina m.
EA201891724A1 (ru) Антитела к tgf-бета2
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
CO2019011458A2 (es) Anticuerpo monoclonal para pd-l1
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
ECSP20024551A (es) ANTICUERPO MONOCLONAL PARA IL-5Ra
EA201892231A1 (ru) Способ очистки белка

Legal Events

Date Code Title Description
FA Abandonment or withdrawal